Welcome to Penzberg. One of Europe s largest biotech facilities
|
|
|
- Job Wilkinson
- 9 years ago
- Views:
Transcription
1 Welcome to Penzbeg One of Euope s lagest biotech facilities
2 The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue
3 Whee it all began The Penzbeg site in 1957
4 Whee it all began The Penzbeg site in 1957 and 2004
5 The Penzbeg site today Founded: 1972 (Boehinge Mannheim) Aea: 310,000 m² Employees: 3,459 (Dec. 03) Invested capital: 870 Mill. (Dec. 03)
6 The Penzbeg site Headcount Numbe of employees *until 2000 incl. Tutzing
7 The Penzbeg site Employee qualifications Advanced taining 8% Technical college gaduates 9% Univesity gaduates 25% Vocational taining 53% unskilled 5%
8 The Penzbeg site Aveage age 38,5 38,4 38,5 38,4 38, * incl. Tutzing until 2000
9 The Penzbeg site Capital expenditue
10 The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue
11 Penzbeg s Role Penzbeg is the only location woldwide whee both divisions have on-site eseach, development and poduction facilities Diagnostics (appox. 2,600 employees) Phama (appox. 710 employees) R & D Reseach Poduction Poduction
12 Penzbeg s Role Biotechnology One of Euope s lagest Biotech facilities Lagest Biotech site in the Roche Goup Supplies poducts fo Diagnostics and Phamaceuticals Most Diagnostics poducts ae biotechnology based Poduces 4 impotant biophamaceuticals
13 The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue
14 Roche Diagnostics Poduct potfolio Life Science Reseach in-vito diagnostics maket Reseach Pofessionals Consumes Applied Science Modula Analytics E 170 Molecula Diagnostics LightCycle Omni S Centalized Diagnostics Nea Patient Testing Accu-Chek Go Cobas Amplipep Diabetes Cae
15 Roche Diagnostics Regional headquates and R&D centes Bugdof Indianapolis Rotkeuz Basel Mannheim Penzbeg Gaz Applied Science Molecula Diagnostics Centalized Diagnostics leasanton/ Alameda Tokyo Nea Patient Testing Diabetes Cae Banchbug Regional headquates Bacelona Singapoe Copoate headquate
16 Penzbeg s Role Diagnostics R&D cente fo eagents in - clinical chemisty - immunology Cente of Excellence fo active ingedients (R&D and Poduction)
17 Biotechnology in Penzbeg Diagnostics Diagnostic eagents and systems Reseach eagents (e.g. estiction enzymes) Industial poducts (e.g. catalase) Enzyme tests (e.g. cholesteol) Immune tests (e.g. tumo makes) Nucleic acid diagnosis (e.g. HIV) Diabetes: Blood suga measuement Enzymes e.g. glucose oxidase
18 The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue
19 Penzbeg s Role Phamaceuticals Diagnostics (appox. 2,600 employees) Phama (appox. 710 employees) R & D Reseach Poduction Poduction
20 The Roche Goup A global leade in biophamaceuticals Roche Goup 1st half 2004 MabThea/Rituxan NeoRecomon/Epogin Pegasys/Copegus Cellcept Heceptin Rocephin Xenical Xeloda Nutopin/Potopin Kytil geen: Biophamaceuticals Sales in CHF m Change H1/2004 vs. H1/ % + 3% + 142% + 19% + 26% + 0% + 0% - 11% + 10% + 13%
21 Penzbeg s Role Phamaceuticals One of 4 Roche s phamaceutical eseach centes Lagest eseach location fo oncology Cente of Excellence fo phamaceutical active ingedients
22 Phama Biologicals Penzbeg Biologicals Tech.Dev. and Manufactuing Biologicals Technical Development Biologicals R&D New Biologicals Manufactuing Biologicals Manufactuing
23 Roche global R&D centes Pleasanton Indianapolis Nutley Palo Alto Genentech Mannheim Penzbeg Penzbeg Basel Rotkeuz Basel RCMG Gaz Phama Biotechnology R&D Centes Chugai Phama Centes Diagnostics Centes Roche Goup
24 Biotechnology poduction in Penzbeg Phamaceuticals Active ingedients fo dugs: - Eythopoietin / Neoecomon - Recombinant plasminogen activato Rapilysin / eteplase - Tastuzumab / Heceptin - Peg-Intefeone-alpha 2a/ Pegasys - Ove 200 antibodies fo diagnostic tests - Active ingedients fo clinical studies Phama biotech poduction Appoved by FDA and EMEA
25 The Roche Goup s lagest biotech facility Site Penzbeg Pofile Role Diagnostics Phamaceuticals Futue
26 The Penzbeg site Biotechnology pojects Building 354 EPO (Eythopoietin) Investment: 182 m Completion: July 2005
27 The Penzbeg site Biotechnology pojects Building 345 Monoclonal antibodies fo Diagnostics Investment: 31.4 m Completion: Mach 2006
28 The Penzbeg site Biotechnology pojects Building 361/362 Bio Heceptin Investment: 290 m Completion: Decembe 07
The future challenges of Healthcare
The futue challenges of Healthcae D. Eich Hunzike CFO F. Hoffmann La Roche Ltd. JPMogan Healthcae Confeence San Fancisco, Januay 12, 2005 This pesentation contains cetain fowad-looking statements. These
Diabetes Care Beyond Meters and Strips
Diabetes Cae Beyond Metes and Stips R&D Day, May 2004 Staffan Ek Head of Diabetes Cae, Roche Diagnostics 1 Roche is well positioned in gowing maket segments Blood Glucose Monitoing maket size 7.3 bn CHF
The relevance of Roche s strategy in the current market environment
Maket dynamics in the Healthcae Industy The elevance of Roche s stategy in the cuent maket envionment D. F.B. Hume, CEO Bank am Bellevue, Januay 2005 This pesentation contains cetain fowad-looking statements.
Significant value in diagnostic information
U.S. Centalized Oveview Tom Adkins Vice Pesident Sales and Maketing Centalized, USA 1 Centalized Significant value in diagnostic infomation Diagnostic analysis of blood and othe body fluids pefomed in
Presentation to analysts Basel, October 14, 2004. Roche YTD Sep '04 Sales, Oct 14, 2004
Roche Thid quate 2004 Pesentation to analysts Basel, Octobe 14, 2004 2 1 This pesentation contains cetain fowad-looking statements. These fowad-looking statements may be identified by wods such as believes,
IT Risk Management. Agenda. Roche at a glance OSI Layers above 7 What we did What we plan to do how to not get shoot
IT Risk Management 30. 2006 ISACA Switzerland Chapter After Hours Seminar Mario Walter Agenda Roche at a glance OSI Layers above 7 What we did What we plan to do how to not get shoot 2006 ISACA After Hours
Roche Diagnostics Positioned for growth
Roche Diagnostics Positioned fo gowth Heino von Pondzynski CEO Division Roche Diagnostics London, Septembe 9th, 2005 1 This pesentation contains cetain fowad-looking statements. These fowad-looking statements
Roche Diagnostics Leading and creating new markets
Roche Leading and ceating new makets Heino von Pondzynski Head of Roche Goldman Sachs UK Roadshow London, May 14 th 2004 This pesentation contains cetain fowad-looking statements. These fowad-looking statements
Point of Care Testing market and Roche
US Point of Cae Oveview Rod Cotton Vice Pesident and Geneal Manage Point of Cae, USA 1 Point of Cae Testing maket and Roche Stategy and futue dives 2 Roche US Event Cotton, Point-of-Cae 1 Point-of-Cae
Focusing on differentiated medicines
Roche Phamaceuticals Focusing on diffeentiated medicines D. Guido Magni Head of Global Medical Science Lehman Bothes Global Healthcae Confeence, Miami, 26 1 This pesentation contains cetain fowad-looking
CRRC-1 Method #1: Standard Practice for Measuring Solar Reflectance of a Flat, Opaque, and Heterogeneous Surface Using a Portable Solar Reflectometer
CRRC- Method #: Standad Pactice fo Measuing Sola Reflectance of a Flat, Opaque, and Heteogeneous Suface Using a Potable Sola Reflectomete Scope This standad pactice coves a technique fo estimating the
Investor Update. Roche posts very strong interim results. Basel, 20 July 2005
Investor Update Basel, 20 July 2005 Roche posts very strong interim results Roche Group Group sales up 17%. Pharmaceutical sales grow three times faster than the global market Operating profit rises 30%,
Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine
Diagnostics Division. Roland Diggelmann COO Roche Diagnostics. Picture
Diagnostics Division Roland Diggelmann COO Roche Diagnostics Picture HY 2013: Roche Group highlights HY 2013 performance Strong Pharma performance, driven by US; solid growth for Diagnostics 12% core EPS
Roche Interim results 2006. Roche Interim Results 2006 July 20, 2006 1
r Roche Interim results 2006 London, July 20, 2006 July 20, 2006 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,
Database Management Systems
Contents Database Management Systems (COP 5725) D. Makus Schneide Depatment of Compute & Infomation Science & Engineeing (CISE) Database Systems Reseach & Development Cente Couse Syllabus 1 Sping 2012
Three months ended 31 March
Media Release Basel, 15 April 2010 Excellent growth in first quarter of 2010 Group sales up 9% in local currencies to 12.2 billion Swiss francs in first three months (+6% in Swiss francs, +15% in US dollars).
Bettina Marcinkowski, Roche Diagnostics GmbH
Roche an attractive employer Academic Recruiting, Career Services & Employer Branding Munich, February 27, 2012 Bettina Marcinkowski, Roche Diagnostics GmbH To share with you Passionate about recruiting
We Innovate Healthcare
Part 2 Roche Annual Report 2006 Finance Report We Innovate Healthcare Innovation spanning the entire healthcare spectrum As a pharmaceuticals and a diagnostics company, Roche brings pioneering products
Life writes the questions We pursue the answers
Life writes the questions We pursue the answers Life writes the questions. 1 What will help me? Can I have hope? When will the others notice? How much life is six months? How bad can it get? Am I alone?
Channel selection in e-commerce age: A strategic analysis of co-op advertising models
Jounal of Industial Engineeing and Management JIEM, 013 6(1):89-103 Online ISSN: 013-0953 Pint ISSN: 013-843 http://dx.doi.og/10.396/jiem.664 Channel selection in e-commece age: A stategic analysis of
The impact of migration on the provision. of UK public services (SRG.10.039.4) Final Report. December 2011
The impact of migation on the povision of UK public sevices (SRG.10.039.4) Final Repot Decembe 2011 The obustness The obustness of the analysis of the is analysis the esponsibility is the esponsibility
Epdf Sulf petroleum, Eflecti and Eeflecti
ANALYSIS OF GLOBAL WARMING MITIGATION BY WHITE REFLECTING SURFACES Fedeico Rossi, Andea Nicolini Univesity of Peugia, CIRIAF Via G.Duanti 67 0615 Peugia, Italy T: +9-075-585846; F: +9-075-5848470; E: [email protected]
Roche Finance Report Roche
2010 Roche Finance Report Table of contents Roche Group 2 Finance in brief 2 Finance 2010 in brief 3 Financial Review 4 Roche Group Consolidated Financial Statements 34 Notes to the Roche Group Consolidated
A framework for the selection of enterprise resource planning (ERP) system based on fuzzy decision making methods
A famewok fo the selection of entepise esouce planning (ERP) system based on fuzzy decision making methods Omid Golshan Tafti M.s student in Industial Management, Univesity of Yazd [email protected]
Drug Discovery in China
Drug Discovery in China Media Visit to Roche in China Shanghai 30 October 2005 Li Chen, Ph. D. Head of Research, Chief Scientific Officer Roche R&D Center (China) Ltd. Research Business Model in China
SNAPSHOT ASIA FIRST IN A SERIES OF REGIONAL SECTOR ANALYSES 2003 OCTOBER. Benchmarking FDI Competitiveness in Asia
FIRST IN A SERIES OF REGIONAL SECTOR ANALYSES 2003 OCTOBER Benchmaking FDI Competitiveness in Asia Copyight 2003 The Wold Bank Goup/MIGA 1818 H Steet, NW Washington, DC 20433 All ights eseved Manufactued
Displacement, Velocity And Acceleration
Displacement, Velocity And Acceleation Vectos and Scalas Position Vectos Displacement Speed and Velocity Acceleation Complete Motion Diagams Outline Scala vs. Vecto Scalas vs. vectos Scala : a eal numbe,
Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced
We Innovate Healthcare
Part 2 Roche Annual Report 2007 Finance Report We Innovate Healthcare We Innovate Healthcare As a research-intensive healthcare company, Roche discovers, develops and provides innovative diagnostic and
+0.1 +3.9 +5.9 +4.5 +1.4
Finance Report Finance in brief Key results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2012 +4.7 2011 +0.1 44.0 40.9 Diagnostics 2012 2011 +3.9 +5.9 21.3 22.4 Group 2012
Magnetic Field and Magnetic Forces. Young and Freedman Chapter 27
Magnetic Field and Magnetic Foces Young and Feedman Chapte 27 Intoduction Reiew - electic fields 1) A chage (o collection of chages) poduces an electic field in the space aound it. 2) The electic field
883 Brochure A5 GENE ss vernis.indd 1-2
ess x a eu / u e a. p o.eu c e / :/ http EURAXESS Reseaches in Motion is the gateway to attactive eseach caees in Euope and to a pool of wold-class eseach talent. By suppoting the mobility of eseaches,
Automated Hydraulic Drilling Rigs. HHSeries
Automated Hydaulic Dilling Rigs HHSeies The Shape of Things to Come CUSTOMSOLUTIONS HH600 Rig The HH Hydaulic Hoist Seies Eveything about the HH Seies is designed fo speed, safety and efficiency. You can
IBM Research Smarter Transportation Analytics
IBM Reseach Smate Tanspotation Analytics Laua Wynte PhD, Senio Reseach Scientist, IBM Watson Reseach Cente [email protected] INSTRUMENTED We now have the ability to measue, sense and see the exact condition
Key figures 2015 CHF millions % change
Media Release Basel, 28 January 2016 Roche reports strong results in 2015 Group sales increased by 5% 1 at constant exchange rates, 1% in Swiss francs Pharmaceuticals Division sales up 5%, driven by oncology
E.S.G. Risk Factors in a Portfolio Context
.S.G. Risk Factos in a Potfolio Context Integated Modeling of nvionmental, Social and Govenance Risk Factos An Innovative Study fo Institutional Investos Novembe/Decembe, 2009 D. Steffen Höte isklab GmbH
Distributed Computing and Big Data: Hadoop and MapReduce
Distibuted Computing and Big Data: Hadoop and Map Bill Keenan, Diecto Tey Heinze, Achitect Thomson Reutes Reseach & Development Agenda R&D Oveview Hadoop and Map Oveview Use Case: Clusteing Legal Documents
FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
AFFILIATE MEMBERSHIP APPLICATION
Califonia Constuction Tucking Association AFFILIATE MEMBERSHIP APPLICATION Reach and Netwok with the Lagest Concentation of Constuction Tucking Fims in the U.S. Affiliate Dues - $500 Annual CCTA 334 N.
Module Availability at Regent s School of Drama, Film and Media Autumn 2016 and Spring 2017 *subject to change*
Availability at Regent s School of Dama, Film and Media Autumn 2016 and Sping 2017 *subject to change* 1. Choose you modules caefully You must discuss the module options available with you academic adviso/
The LCOE is defined as the energy price ($ per unit of energy output) for which the Net Present Value of the investment is zero.
Poject Decision Metics: Levelized Cost of Enegy (LCOE) Let s etun to ou wind powe and natual gas powe plant example fom ealie in this lesson. Suppose that both powe plants wee selling electicity into the
College of Engineering Bachelor of Computer Science
2 0 0 7 w w w. c n u a s. e d u College of Engineeing Bachelo of Compute Science This bochue Details the BACHELOR OF COMPUTER SCIENCE PROGRAM available though CNU s College of Engineeing. Fo ou most up-to-date
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from three Phase III studies of the
Media Release Basel, 12 April 2016 Roche to present new data at AAN showing superior efficacy of investigational medicine ocrelizumab versus comparators on disease activity and progression in two forms
cover comparison TUH it s my health fund! Your Queensland health fund Effective 2 April 2014
Effective 2 Apil 2014 You Queensland health fund cove compaison TUH it s my health fund! PLEASE CAREFULLY READ AND RETAIN THIS BROCHURE. PLEASE READ IN CONJUNCTION WITH THE Fine Points BROCHURE. waiting
Ilona V. Tregub, ScD., Professor
Investment Potfolio Fomation fo the Pension Fund of Russia Ilona V. egub, ScD., Pofesso Mathematical Modeling of Economic Pocesses Depatment he Financial Univesity unde the Govenment of the Russian Fedeation
How Much Should a Firm Borrow. Effect of tax shields. Capital Structure Theory. Capital Structure & Corporate Taxes
How Much Should a Fim Boow Chapte 19 Capital Stuctue & Copoate Taxes Financial Risk - Risk to shaeholdes esulting fom the use of debt. Financial Leveage - Incease in the vaiability of shaeholde etuns that
Fixed Income Attribution: Introduction
18th & 19th Febuay 2015, Cental London Fixed Income Attibution: A compehensive undestanding of Fixed Income Attibution and the challenging data issues aound this topic Delegates attending this two-day
YARN PROPERTIES MEASUREMENT: AN OPTICAL APPROACH
nd INTERNATIONAL TEXTILE, CLOTHING & ESIGN CONFERENCE Magic Wold of Textiles Octobe 03 d to 06 th 004, UBROVNIK, CROATIA YARN PROPERTIES MEASUREMENT: AN OPTICAL APPROACH Jana VOBOROVA; Ashish GARG; Bohuslav
ON THE (Q, R) POLICY IN PRODUCTION-INVENTORY SYSTEMS
ON THE R POLICY IN PRODUCTION-INVENTORY SYSTEMS Saifallah Benjaafa and Joon-Seok Kim Depatment of Mechanical Engineeing Univesity of Minnesota Minneapolis MN 55455 Abstact We conside a poduction-inventoy
CONCEPTUAL FRAMEWORK FOR DEVELOPING AND VERIFICATION OF ATTRIBUTION MODELS. ARITHMETIC ATTRIBUTION MODELS
CONCEPUAL FAMEOK FO DEVELOPING AND VEIFICAION OF AIBUION MODELS. AIHMEIC AIBUION MODELS Yui K. Shestopaloff, is Diecto of eseach & Deelopment at SegmentSoft Inc. He is a Docto of Sciences and has a Ph.D.
FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition
Table of Contents. Key figures 3
Key figures 3 Group and Divisional Results 4 Overview 4 Pharmaceuticals 5 Diagnostics 7 Vitamins and Fine Chemicals 7 Group operating results 8 Financial income 8 Cash flows 8 Financial condition 9 Outlook
GESTÃO FINANCEIRA II PROBLEM SET 1 - SOLUTIONS
GESTÃO FINANCEIRA II PROBLEM SET 1 - SOLUTIONS (FROM BERK AND DEMARZO S CORPORATE FINANCE ) LICENCIATURA UNDERGRADUATE COURSE 1 ST SEMESTER 2010-2011 Chapte 1 The Copoation 1-13. What is the diffeence
MEDIA KIT Texas Aggregates & Concrete Association
MEDIA KIT Texas Aggegates & Concete Association Solidify you band to membes who spend $350 million on poducts and sevices each yea. TACA Conveyo magazine pint & digital Membeship Diectoy & Resouce Guide
FXA 2008. Candidates should be able to : Describe how a mass creates a gravitational field in the space around it.
Candidates should be able to : Descibe how a mass ceates a gavitational field in the space aound it. Define gavitational field stength as foce pe unit mass. Define and use the peiod of an object descibing
PlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many
Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols
Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols For questions on the content of this document contact Leonard Wilson, CBER at 301-827-0373 or Susan Johnson, CDER
An Introduction to Omega
An Intoduction to Omega Con Keating and William F. Shadwick These distibutions have the same mean and vaiance. Ae you indiffeent to thei isk-ewad chaacteistics? The Finance Development Cente 2002 1 Fom
Committed to innovation and growth
Committed to innovation and growth Alan Hippe, CFO Roche Group London, September 2012 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
Broad Selection of Antibodies & Antigens. for the Diagnostics Industry in North America
Broad Selection of Antibodies & Antigens for the Diagnostics Industry in North America Antibodies and Antigens for Diagnostics Diagnostics manufacturers require antibodies and antigens of proven quality
Controlling the Money Supply: Bond Purchases in the Open Market
Money Supply By the Bank of Canada and Inteest Rate Detemination Open Opeations and Monetay Tansmission Mechanism The Cental Bank conducts monetay policy Bank of Canada is Canada's cental bank supevises
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
Open Economies. Chapter 32. A Macroeconomic Theory of the Open Economy. Basic Assumptions of a Macroeconomic Model of an Open Economy
Chapte 32. A Macoeconomic Theoy of the Open Economy Open Economies An open economy is one that inteacts feely with othe economies aound the wold. slide 0 slide 1 Key Macoeconomic Vaiables in an Open Economy
The Impact of Intel in Costa Rica
The Impact of Intel in Costa Rica Nine Yeas Afte the Decision to Invest Investing in Development Seies Multilateal Investment Guaantee Agency 2006 Copyight 2006 The Wold Bank Goup/MIGA 1818 H Steet, NW
INVESTIGATION OF FLOW INSIDE AN AXIAL-FLOW PUMP OF GV IMP TYPE
1 INVESTIGATION OF FLOW INSIDE AN AXIAL-FLOW PUMP OF GV IMP TYPE ANATOLIY A. YEVTUSHENKO 1, ALEXEY N. KOCHEVSKY 1, NATALYA A. FEDOTOVA 1, ALEXANDER Y. SCHELYAEV 2, VLADIMIR N. KONSHIN 2 1 Depatment of
Spirotechnics! September 7, 2011. Amanda Zeringue, Michael Spannuth and Amanda Zeringue Dierential Geometry Project
Spiotechnics! Septembe 7, 2011 Amanda Zeingue, Michael Spannuth and Amanda Zeingue Dieential Geomety Poject 1 The Beginning The geneal consensus of ou goup began with one thought: Spiogaphs ae awesome.
How to SYSPREP a Windows 7 Pro corporate PC setup so you can image it for use on future PCs
AnswesThatWok TM How to SYSPREP a Windows 7 Po copoate PC setup so you can image it fo use on futue PCs In a copoate envionment most PCs will usually have identical setups, with the same pogams installed
YIELD TO MATURITY ACCRUED INTEREST QUOTED PRICE INVOICE PRICE
YIELD TO MATURITY ACCRUED INTEREST QUOTED PRICE INVOICE PRICE Septembe 1999 Quoted Rate Teasuy Bills [Called Banke's Discount Rate] d = [ P 1 - P 1 P 0 ] * 360 [ N ] d = Bankes discount yield P 1 = face
NEW LONDON STATE PIER PROPERTY CHARACTERISTICS
NEW LONDON STATE PIER PROPERTY CHARACTERISTICS PROPERTY CHARACTERISTICS The is situated in Southeasten, Connecticut appoximately 100 miles south of Boston, Massachusetts and 130 miles notheast of New Yok
Biotechnology for the World The Roche site Penzberg
Biotechnology for the World The Roche site Penzberg Kopfleiste zum ausfüllen 2 Biotechnology in Penzberg Research, development & production in Penzberg Penzberg Key site for biotech The Bavarian Roche
Contents. Overview 02 Who we are 04 What we do 06 2015 highlights 08 Chairman s shareholder letter 14 CEO s shareholder letter
Annual Report 2015 P A T I E N T S Positive late-stage clinical study results on our investigational medicine ocrelizumab in multiple sclerosis give hope to people living with this disease who need more
INTEGRATION AND COMPETITION IN THE EUROPEAN FINANCIAL MARKETS * Juan Fernández de Guevara, Joaquín Maudos and Francisco Pérez **
INTEGRATION AN COMPETITION IN THE EUROPEAN FINANCIA MARKETS * Juan Fenández de Guevaa, Joaquín Maudos and Fancisco Péez ** WP-EC 2003-12 Coesponding autho: Joaquín Maudos, Instituto Valenciano de Investigaciones
Software Engineering and Development
I T H E A 67 Softwae Engineeing and Development SOFTWARE DEVELOPMENT PROCESS DYNAMICS MODELING AS STATE MACHINE Leonid Lyubchyk, Vasyl Soloshchuk Abstact: Softwae development pocess modeling is gaining
F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland. All trademarks are legally protected. www.roche.com. Finance Report 2015. Roche
F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland 2016 All trademarks are legally protected. www.roche.com Roche Finance Report 2015 0 000 000 E Finance Report 2015 Finance in brief Key results Sales CER
Application for Admission GENEVA COLLEGE
Application fo Admission GENEVA COLLEGE 3 2 0 0 C o l l e g e A v e n u e, B e a v e F a l l s, P A 1 5 0 1 0 Application Instuctions When to apply You may apply fo admission any time afte you junio yea